Question to the Department of Health and Social Care:

To ask His Majesty's Government what plans they have to review Gloucestershire Integrated Care Board’s (ICB) policy on liothyronine to assess the extent to which it (1) follows national guidance, by asking new patients who have already been reviewed by specialist NHS consultants to be reviewed again if they move into Gloucestershire from another ICB area, and (2) incurs higher costs and additional use of NHS resources.

The Department has no plans for a review. The current Gloucestershire Integrated Care Board guidance on the prescribing of liothyronine, agreed by the former Gloucestershire Clinical Commissioning Group in April 2022, is under a local review to be completed within the next four months and will consider the position on new patients already on liothyronine moving into Gloucestershire.